Bevacizumab, an anti–vascular endothelial growth factor (VEGF) antibody, was approved in 2009 to treat glioblastoma recurrence on the basis of encouraging preclinical and clinical results [2, 3]. The gene discussed is VEGFA; the disease is glioblastoma.